ARTICLE | Product Development
PPH studies continue to dog Redux
August 19, 1996 7:00 AM UTC
Interneuron Pharmaceuticals Inc. (IPIC) advised investors in its 10Q filing that the New England Journal of Medicine soon will publish a study that will show a higher incidence of a lung disorder called primary pulmonary hypertension (PPH) in patients using anorectic drugs, which include IPIC's Redux dexfenfluramine.
PPH is an extremely rare, but fatal, complication associated with anorectic drugs. It also is associated with obesity, making it difficult to separate the effect of drugs from the underlying condition...